Selected research
Industry Research
Liver Cirrhosis Industry Research Report 2026
Market perspective
The global Liver Cirrhosis market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Liver Cirrhosis market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Liver Cirrhosis market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Liver Cirrhosis market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Liver Cirrhosis include Johnson & Johnson, Merck, GlaxoSmithKline, Bristol-Myers Squibb, Intercept Pharmaceuticals, Instituto Grifols, Gwo Xi Stem Cell Applied Technology, Gilead Sciences and F Hoffman La-Roche and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Liver Cirrhosis market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Liver Cirrhosis.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Liver Cirrhosis Market by Company
Johnson & Johnson
Merck
GlaxoSmithKline
Bristol-Myers Squibb
Intercept Pharmaceuticals
Instituto Grifols
Gwo Xi Stem Cell Applied Technology
Gilead Sciences
F Hoffman La-Roche
Conatus Pharmaceuticals
Liver Cirrhosis Segment by Type
Cryptogenic Cirrhosis
Cardiac Cirrhosis
Atrophic Cirrhosis
Alcoholic Cirrhosis
Biliary Cirrhosis
Liver Cirrhosis Segment by Application
Hospitals
Specialty Clinics
Liver Cirrhosis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liver Cirrhosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Liver Cirrhosis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liver Cirrhosis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Liver Cirrhosis companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cryptogenic Cirrhosis
- Cardiac Cirrhosis
- Atrophic Cirrhosis
- Alcoholic Cirrhosis
- Biliary Cirrhosis
Applications
- Hospitals
- Specialty Clinics
Companies covered
- Johnson & Johnson
- Merck
- GlaxoSmithKline
- Bristol-Myers Squibb
- Intercept Pharmaceuticals
- Instituto Grifols
- Gwo Xi Stem Cell Applied Technology
- Gilead Sciences
- F Hoffman La-Roche
- Conatus Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Liver Cirrhosis by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Cryptogenic Cirrhosis
- 2.2.3 Cardiac Cirrhosis
- 2.2.4 Atrophic Cirrhosis
- 2.2.5 Alcoholic Cirrhosis
- 2.2.6 Biliary Cirrhosis
- 2.3 Liver Cirrhosis by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospitals
- 2.3.3 Specialty Clinics
- 2.4 Assumptions and Limitations
3 Liver Cirrhosis Breakdown Data by Type
- 3.1 Global Liver Cirrhosis Historic Market Size by Type (2021-2026)
- 3.2 Global Liver Cirrhosis Forecasted Market Size by Type (2027-2032)
4 Liver Cirrhosis Breakdown Data by Application
- 4.1 Global Liver Cirrhosis Historic Market Size by Application (2021-2026)
- 4.2 Global Liver Cirrhosis Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Liver Cirrhosis Market Perspective (2021-2032)
- 5.2 Global Liver Cirrhosis Growth Trends by Region
- 5.2.1 Global Liver Cirrhosis Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Liver Cirrhosis Historic Market Size by Region (2021-2026)
- 5.2.3 Liver Cirrhosis Forecasted Market Size by Region (2027-2032)
- 5.3 Liver Cirrhosis Market Dynamics
- 5.3.1 Liver Cirrhosis Industry Trends
- 5.3.2 Liver Cirrhosis Market Drivers
- 5.3.3 Liver Cirrhosis Market Challenges
- 5.3.4 Liver Cirrhosis Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Liver Cirrhosis Players by Revenue
- 6.1.1 Global Top Liver Cirrhosis Players by Revenue (2021-2026)
- 6.1.2 Global Liver Cirrhosis Revenue Market Share by Players (2021-2026)
- 6.2 Global Liver Cirrhosis Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Liver Cirrhosis Head Office and Area Served
- 6.4 Global Liver Cirrhosis Players, Product Type & Application
- 6.5 Global Liver Cirrhosis Manufacturers Established Date
- 6.6 Global Liver Cirrhosis Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Liver Cirrhosis Market Size (2021-2032)
- 7.2 North America Liver Cirrhosis Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Liver Cirrhosis Market Size by Country (2021-2026)
- 7.4 North America Liver Cirrhosis Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Liver Cirrhosis Market Size (2021-2032)
- 8.2 Europe Liver Cirrhosis Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Liver Cirrhosis Market Size by Country (2021-2026)
- 8.4 Europe Liver Cirrhosis Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Liver Cirrhosis Market Size (2021-2032)
- 9.2 Asia-Pacific Liver Cirrhosis Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Liver Cirrhosis Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Liver Cirrhosis Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Liver Cirrhosis Market Size (2021-2032)
- 10.2 South America Liver Cirrhosis Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Liver Cirrhosis Market Size by Country (2021-2026)
- 10.4 South America Liver Cirrhosis Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Liver Cirrhosis Market Size (2021-2032)
- 11.2 Middle East & Africa Liver Cirrhosis Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Liver Cirrhosis Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Liver Cirrhosis Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Johnson & Johnson
- 12.1.1 Johnson & Johnson Company Information
- 12.1.2 Johnson & Johnson Business Overview
- 12.1.3 Johnson & Johnson Revenue in Liver Cirrhosis Business (2021-2026)
- 12.1.4 Johnson & Johnson Liver Cirrhosis Product Portfolio
- 12.1.5 Johnson & Johnson Recent Developments
- 12.2 Merck
- 12.2.1 Merck Company Information
- 12.2.2 Merck Business Overview
- 12.2.3 Merck Revenue in Liver Cirrhosis Business (2021-2026)
- 12.2.4 Merck Liver Cirrhosis Product Portfolio
- 12.2.5 Merck Recent Developments
- 12.3 GlaxoSmithKline
- 12.3.1 GlaxoSmithKline Company Information
- 12.3.2 GlaxoSmithKline Business Overview
- 12.3.3 GlaxoSmithKline Revenue in Liver Cirrhosis Business (2021-2026)
- 12.3.4 GlaxoSmithKline Liver Cirrhosis Product Portfolio
- 12.3.5 GlaxoSmithKline Recent Developments
- 12.4 Bristol-Myers Squibb
- 12.4.1 Bristol-Myers Squibb Company Information
- 12.4.2 Bristol-Myers Squibb Business Overview
- 12.4.3 Bristol-Myers Squibb Revenue in Liver Cirrhosis Business (2021-2026)
- 12.4.4 Bristol-Myers Squibb Liver Cirrhosis Product Portfolio
- 12.4.5 Bristol-Myers Squibb Recent Developments
- 12.5 Intercept Pharmaceuticals
- 12.5.1 Intercept Pharmaceuticals Company Information
- 12.5.2 Intercept Pharmaceuticals Business Overview
- 12.5.3 Intercept Pharmaceuticals Revenue in Liver Cirrhosis Business (2021-2026)
- 12.5.4 Intercept Pharmaceuticals Liver Cirrhosis Product Portfolio
- 12.5.5 Intercept Pharmaceuticals Recent Developments
- 12.6 Instituto Grifols
- 12.6.1 Instituto Grifols Company Information
- 12.6.2 Instituto Grifols Business Overview
- 12.6.3 Instituto Grifols Revenue in Liver Cirrhosis Business (2021-2026)
- 12.6.4 Instituto Grifols Liver Cirrhosis Product Portfolio
- 12.6.5 Instituto Grifols Recent Developments
- 12.7 Gwo Xi Stem Cell Applied Technology
- 12.7.1 Gwo Xi Stem Cell Applied Technology Company Information
- 12.7.2 Gwo Xi Stem Cell Applied Technology Business Overview
- 12.7.3 Gwo Xi Stem Cell Applied Technology Revenue in Liver Cirrhosis Business (2021-2026)
- 12.7.4 Gwo Xi Stem Cell Applied Technology Liver Cirrhosis Product Portfolio
- 12.7.5 Gwo Xi Stem Cell Applied Technology Recent Developments
- 12.8 Gilead Sciences
- 12.8.1 Gilead Sciences Company Information
- 12.8.2 Gilead Sciences Business Overview
- 12.8.3 Gilead Sciences Revenue in Liver Cirrhosis Business (2021-2026)
- 12.8.4 Gilead Sciences Liver Cirrhosis Product Portfolio
- 12.8.5 Gilead Sciences Recent Developments
- 12.9 F Hoffman La-Roche
- 12.9.1 F Hoffman La-Roche Company Information
- 12.9.2 F Hoffman La-Roche Business Overview
- 12.9.3 F Hoffman La-Roche Revenue in Liver Cirrhosis Business (2021-2026)
- 12.9.4 F Hoffman La-Roche Liver Cirrhosis Product Portfolio
- 12.9.5 F Hoffman La-Roche Recent Developments
- 12.10 Conatus Pharmaceuticals
- 12.10.1 Conatus Pharmaceuticals Company Information
- 12.10.2 Conatus Pharmaceuticals Business Overview
- 12.10.3 Conatus Pharmaceuticals Revenue in Liver Cirrhosis Business (2021-2026)
- 12.10.4 Conatus Pharmaceuticals Liver Cirrhosis Product Portfolio
- 12.10.5 Conatus Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst